A Personalized Rasayana therapy to improve quality of life

Not Applicable

Conditions: Health Condition 1: C15-C26- Malignant neoplasms of digestive organs

Registration Number: CTRI/2020/10/028281

Lead Sponsor: Rasayu Cancer Clinic Pune

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1 Histopathologically diagnosed Patients with gastrointestinal cancer which includes stomach colorectal pancreas esophagus Liver cancers etc

2 Male and Female patient above the age of 60 years

3 Patients who are ineligible to receive conventional anticancer therapy

4 Patients for whom no conventional anticancer therapy exist

5 Those that are willingly refusing conventional anticancer therapy with the reason known

6 Patients having resistance to conventional therapies like chemotherapy,immunotherapy etc

7.Patients who are willing to take exclusively Rasayana therapy

Exclusion Criteria

1 Patients taking any other conventional or alternative treatment which is known to significantly impact Patients Quality of life

2 Patients receiving any conventional anticancer therapy

3 Patients with any psychiatric disturbance major depression psychosis which will impair Patients ability to respond the questions in QoL questionnaire

4 Patients with cerebral mets

5 Patients with taking analgesics

6 Patients with expected survival of less than 3 months

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br/ ><br>To evaluate the efficacy of Rasayana therapy in improving health related QoL , Physical performance status and identify its impact on survivalTimepoint: Pre and post therapy- monthly Quality of life and physical performance status will be assessed by FACT G scale and ECOG measuring tool upto 3 months and patient will be observed for overall survival further upto 1 or more than 1 year <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
To evaluate the Safety and tolerability of Rasayana therapy <br/ ><br> <br/ ><br>To evaluate impact of Rasayana therapy on gastrointestinal tumorsTimepoint: Safety will be assessed at baseline and bimonthly with heamatological and biochemical parameters and by CTCAE V 5 criteria <br/ ><br> <br/ ><br>Tumour response will be assessed by Radiological assessment with PET-CT scan at baseline and post therapy at 6 months